Free Newsletter
Genzyme CEO's 2008 paycheck: $13.7M
Another chief executive jumps onto our list of $10 million-plus men. Genzyme chief Henri Termeer took down total compensation of $13.7 million last year, according to SEC documents (via the Boston Business Journal).
Termeer got a base salary of $1.6 million, plus $7.8 million in options and $2.3 million in stock. His cash incentive comp? Almost $2 million.
As you know, Genzyme turns out specialty biotech meds for rare disorders such as Pompe disease and Gaucher's disease. Its production of Myozyme, the Pompe remedy, has run into some snags as the FDA declared that the company would have to submit a separate app for large-scale production of the drug. The large-batch version was dubbed Lumizyme. Just last week Genzyme got a "complete response letter" from the FDA asking for a postapproval verification study of Lumizyme, plus a risk-management plan, as conditions for approval.
- see the Business Journal story
Related Articles:
Ranking pharma's highest-paid execs
Mylan execs' pay leaps by 41%
Amid proxy fight, Biogen chief earns $11.3M
Wyeth CEO in line for $53M handshake
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: